Gina Mazzariello Sells 9,536 Shares of Amylyx Pharmaceuticals (NASDAQ:AMLX) Stock

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) insider Gina Mazzariello sold 9,536 shares of the stock in a transaction that occurred on Thursday, September 10th. The shares were sold at an average price of $32.46, for a total value of $309,538.56. Following the transaction, the insider owned 190,838 shares in the company, valued at approximately $6,194,601.48. This trade represents a 4.76% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Gina Mazzariello also recently made the following trade(s):

• On Thursday, July 9th, Gina Mazzariello sold 15,000 shares of Amylyx Pharmaceuticals stock. The shares were sold at an average price of $18.32, for a total transaction of $274,800.00.

Amylyx Pharmaceuticals Trading Down 1.5%

Shares of Amylyx Pharmaceuticals stock opened at $33.15 on Wednesday. The firm has a fifty day simple moving average of $26.31 and a 200-day simple moving average of $19.13. Amylyx Pharmaceuticals, Inc. has a 1-year low of $10.83 and a 1-year high of $41.14. The stock has a market capitalization of $3.69 billion, a price-to-earnings ratio of -23.18 and a beta of -0.13.

Amylyx Pharmaceuticals (NASDAQ:AMLX) last posted its quarterly earnings data on Thursday, August 6th. The company reported ($0.39) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.36) by ($0.03). As a group, research analysts predict that Amylyx Pharmaceuticals, Inc. will post -1.48 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in AMLX. BlackRock Inc. bought a new stake in shares of Amylyx Pharmaceuticals in the second quarter valued at about $158,534,000. GSA Capital Partners LLP acquired a new stake in Amylyx Pharmaceuticals during the second quarter worth about $705,000. Dimensional Fund Advisors LP increased its stake in Amylyx Pharmaceuticals by 17.1% during the first quarter. Dimensional Fund Advisors LP now owns 903,192 shares of the company’s stock valued at $12,544,000 after acquiring an additional 131,944 shares during the period. Connor Clark & Lunn Investment Management Ltd. bought a new position in Amylyx Pharmaceuticals during the second quarter valued at about $12,949,000. Finally, Elmind Capital LP acquired a new position in Amylyx Pharmaceuticals in the 2nd quarter valued at approximately $2,011,520. Institutional investors own 95.84% of the company’s stock.

Wall Street Analyst Weigh In

AMLX has been the topic of several research analyst reports. Guggenheim raised their price target on Amylyx Pharmaceuticals from $55.00 to $57.00 and gave the company a “buy” rating in a research report on Thursday, August 27th. Weiss Ratings reissued a “sell (d-)” rating on shares of Amylyx Pharmaceuticals in a research report on Wednesday, August 5th. HC Wainwright increased their target price on Amylyx Pharmaceuticals from $34.00 to $55.00 and gave the company a “buy” rating in a research note on Tuesday, August 18th. Robert W. Baird raised their target price on Amylyx Pharmaceuticals from $28.00 to $52.00 and gave the company an “outperform” rating in a report on Wednesday, August 19th. Finally, Mizuho lifted their price target on Amylyx Pharmaceuticals from $30.00 to $42.00 and gave the stock an “outperform” rating in a research report on Tuesday, August 18th. Two equities research analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Buy” and a consensus target price of $38.86.

Amylyx Pharmaceuticals Company Profile